Global pharmaceutical leaders are deploying hundreds of billions of dollars to scale U.S. manufacturing infrastructure, expand research facilities, and insulate global supply chains from potential tariff impacts.
📊 Key Mega-Investments & Major Capital Commitments
- AbbVie ($100B): Pledged $100 billion over 10 years for U.S. R&D under a 3-year pricing agreement, including $380 million for neuroscience and obesity production in Illinois.
- Pfizer ($70B): Secured a 3-year tariff exemption deal following a $70 billion commitment toward domestic R&D and manufacturing.
- Merck ($70B+): Building a $3 billion facility in Virginia, a $1 billion Keytruda plant in Delaware, and an $895 million Kansas expansion for animal health.
- Eli Lilly ($50B+): Spending over $27 billion across four new plants, including a $3.5 billion facility in Pennsylvania to expand GLP-1/biologic supply chains.
- Johnson & Johnson ($55B): Increasing U.S. investments by 25% over four years, building four major facilities across North Carolina and Florida.
- AstraZeneca ($50B) & Roche ($50B+): AstraZeneca is funding a major Virginia drug substance facility through 2030, while Roche expanded its Holly Springs, NC site to $2 billion alongside an Indianapolis hub expansion.
- Novartis ($23B) & Sanofi ($20B+): Novartis is building six new factories and expanding in San Diego; Sanofi is scaling U.S. production and contract partnerships.
💡 Specialty & Regional Player Expansions
- Gilead Sciences ($32B Total): Added $11 billion in new U.S. commitments, beginning construction on a Foster City, CA manufacturing hub.
- Bristol Myers Squibb ($40B Total): Investing $2.3 billion for a new cell therapy/drug facility in Houston, Texas.
- Amgen ($3.4B+): Expanding plants across Ohio ($1.4B), North Carolina ($1B), California ($600M), and Puerto Rico ($950M).
- Biogen ($2B) & CSL ($1.5B): Biogen is building out its 8th North Carolina factory, while CSL is expanding plasma therapy manufacturing in Illinois.
💡 The Strategic Takeaway
Faced with trade friction and potential pharmaceutical tariffs, global drugmakers are near-shoring production to the world’s largest market. This $500B capital deployment secures supply chains, accelerates domestic job growth, and protects revenue streams against geopolitical shocks.